蕲蛇酶与疏血通治疗缺血性脑血管疾病的最小成本分析  

Cost-minimization Analysis of Acutase vs. Shuxuetong for Ischemic Cerebral Vascular Diseases

作　　者：颜陶[1] 万先惠 费慧芝[1] 代先坤 胡小娅[1] 周岐新[1] 

机构地区：[1]重庆医科大学临床药学研究室,重庆市400016 [2]重庆市花溪医院药剂科,重庆市400054

出　　处：《中国药房》2011年第12期1111-1113,共3页China Pharmacy

摘　　要：目的:评价蕲蛇酶和疏血通治疗缺血性脑血管疾病的经济学效果。方法:选取2009年重庆市花溪医院缺血性脑血管疾病患者80例,均分为蕲蛇酶组和疏血通组,分别计算2组的治疗成本和有效率,做经济学分析。结果:蕲蛇酶组平均成本为890.90元,有效率为70%;疏血通组平均成本为1235.66元,有效率为75%;2组有效率比较,差异无统计学意义。按"新农合"比例报销后蕲蛇酶组自付费用不变,疏血通组自付费用为820.08元。结论:自费患者用蕲蛇酶成本较低,"新农合"患者用疏血通更省。但可能随"新农合"政策的调整而变动。To analyze and compare the cost and effect of acutase vs. Shuxuetong injection for ischemic cerebral vascular diseases. METHODS： 80 cases of ischemic cerebral vascular diseases collected from Chongqing Huaxi Hospital in 2009 were divided into acutase group and shuxuetong group for a retrospective pharmacoeconomic analysis. Two groups were balanced in sex, age and patients＇ conditions, and there was no significant difference （P〉0.05）. The costs and effective rate of two groups were calculated respectively. RESULTS： The average cost of acutase group was 890.90 yuan with effective rate of 70%. The average cost of shuxuetong group was 1 235.66 yuan with effective rate of 75%. There was no significant difference in effective rate between 2 groups. In according to the regulations of New Rural Cooperative Medical Insurance （NRCMI）, the payment of t acutase group remained unchanged while that of shuxuetong group was 820.08 yuan. CONCLUSION： Based on the minimum costs, patients who pay for medical service by themselves should choose acutase for treatment and patients joining the NRCMI can use Shuxuetong injection. However, it may be alternated with the change of NRCMI policy.

关 键 词：蕲蛇酶 疏血通 缺血性脑血管病 药物经济学 最小成本分析 

分 类 号：R543[医药卫生—心血管疾病]